© 2002 American Thoracic Society DOI: 10.1165/rcmb.2001-0014OC Altered Zinc Homeostasis and Caspase-3 Activity in Murine Allergic Airway InflammationDepartment of Medicine, University of Adelaide, The Queen Elizabeth Hospital, Woodville, South Australia; Division of Biochemistry and Molecular Biology, John Curtin School of Medical Research, Australian National University, Canberra, A.C.T.; and Department of Clinical Biochemistry, Institute of Medical and Veterinary Science, South Australia, Australia. Address correspondence to: Dr P. Zalewski, Department of Medicine, University of Adelaide, The Queen Elizabeth Hospital, Woodville, South Australia, 5011 Australia. E-mail: peter.zalewski{at}adelaide.edu.au
Zn may have an important protective role in the respiratory epithelium and Zn deficiency may enhance airway inflammation and epithelial damage. The effects of mild nutritional Zn deficiency on airway hyperresponsiveness (AHR) and airway inflammation in mice sensitized and challenged with ovalbumin (OVA) to induce an allergic response were investigated. Balb/c mice were given Zn normal (ZN, 50 mg/kg Zn) or Zn limited diets (ZL, 14 mg/kg Zn) before and during induction of allergic airway inflammation, with appropriate controls (saline-treated, SAL). ZL mice had greater levels of AHR than ZN mice, regardless of presence or absence of allergic inflammation. These mice also had increased eosinophilia and mucus cell hyperplasia compared with ZN mice. Second, ZN and ZL OVA-treated mice had significant decreases in airway epithelial Zinquin fluorescence, indicating a lowered availability of Zn compared with their SAL-treated counterparts. In contrast, the pro-apoptotic protein caspase-3, which was co-localized with Zn in the apical epithelium, was significantly increased in both ZN and ZL OVA-treated mice. Immunologically active caspase-3 and apoptosis were increased in OVA-treated mice, especially the ZL group. These findings provide the first data for adverse effects of Zn deficiency on the respiratory epithelium and support a role for altered Zn homeostasis and caspase upregulation in asthma.
Abbreviations: airway hyperreactivity, AHR bronchoalveolar lavage fluid, BALF basement membrane, BM bovine serum albumin, BSA fluoroscein isothiocyanate, FITC grey scale intensity units, GSU Hanks' balanced saline solution, HBSS high power field, HPF lumen, LM metallothionein, MT Optimum Cooling Tissue Medium, OCT ovalbumin, OVA phosphate-buffered saline, PBS saline, SAL N,N,N',N'-tetrakis(2-pyridylmethyl)ethyl-enediamine, TPEN Zn-limited, ZL Zn normal, ZN zinc, Zn
Asthma is a chronic inflammatory disorder of the airways in which the recruitment and activation of inflammatory cells such as eosinophils, mast cells, and neutrophils play a major role in the pathogenesis of this disease (1). Suboptimally-controlled asthma is also accompanied by hypersecretion of mucus, variable airways obstruction, and enhanced airway hyperresponsiveness (AHR). One major pathologic feature of asthma is the shedding and desquamation of the respiratory epithelium. Bronchial biopsies taken from patients with asthma commonly demonstrate loss of the mucosal epithelium, and the swelling of ciliated columnar cells, giving the epithelium a "fragile appearance" (2). It has been suggested that increased release of serine proteases from neutrophils recruited during airway inflammation may be responsible for the detachment of human epithelial cells from their basement membrane (3). Because apoptotic pathways can be targeted by specific inhibitors (4, 5), it is important to determine whether epithelial cells die by apoptosis resulting in shedding. Although it is a normal process, the regulation of apoptosis becomes altered in some chronic diseases, such as HIV and diabetes (6). Recently, it has been shown that the apoptotic caspase-3 protein was increased in the epithelium and submucosa of human bronchial biopsies from individuals with asthma, both steroid-treated and -untreated, when compared with subjects without asthma (7). Zn is an important regulator of caspase-3, as well as an antioxidant, microtubule stabilizer, growth co-factor, and anti-inflammatory agent (8). Over the past 30 yr, many researchers have demonstrated the important role of Zn in a variety of physiologic processes, including growth and development, maintenance and priming of the immune system, and in tissue repair and regeneration. Zn is one of the most widely distributed biometals found in living tissues and secretions and is transported loosely bound to albumin in the circulation (9). In our previous studies, using a novel Zn-specific fluorophore (Zinquin), we have shown that Zn is a cellular regulator of caspase-3 activation and that it is co-localized with the zymogen form of caspase-3 in the apical cytoplasm of sheep and human airway epithelial cells (10). Furthermore, depletion of available Zn in these cells leads to rapid activation of caspase-3, culminating in apoptosis (11). The increase in prevalence of asthma has been linked to environmental factors, including diet (12). Several studies have reported an association between asthma and low hair and serum Zn levels (1317). In another study, a negative relationship was found between wheezing and serum Zn:Cu ratio in a large population within the United States (n = 9,074) (18). Furthermore, in an investigation into the relationship between allergic diseases and dietary antioxidants, it was noted that there was an increase in the presence of atopy, bronchial reactivity, and the risk of allergic-type symptoms in adults with the lowest intake of dietary Zn (19). The significance of the association between asthma symptoms, low serum Zn levels, and low dietary Zn intake is not yet fully understood. In this investigation, we have used a well-established murine model of allergic airway inflammation (20) to examine:(i) the influence of dietary Zn on AHR and airway inflammation in saline (SAL)-treated and ovalbumin (OVA)-treated mice, and (ii) the influence of allergic inflammation per se on Zn and procaspase-3 levels in respiratory epithelial cells.
Animals Specific pathogenfree 4-wk-old female Balb/c mice were purchased from the University of Adelaide Animal Center, Adelaide, South Australia. Weight-matched mice were housed together in groups of eight in plastic cages with stainless steel grid floors (38 cm x 25 cm, 5 mm mesh, 1 mm wire diameter to minimize coprophagy). Animals were housed at 21°C with a 14-h light/10-h dark cycle. All experiments conformed to National Health and Medical Research Council Guidelines and were approved by the animal ethics committees of The Queen Elizabeth Hospital and The University of Adelaide.
Induction of Mild Zn Deprivation and Allergic Airway Inflammation in Balb/c Mice
Allergic inflammation was induced using the method of Xiong and coworkers (20) with modifications (Figure 1) . Briefly, mice on both ZN and ZL diets were injected intraperitoneally on Days 1 and 12 with 50 µg of OVA (Sigma-Aldrich, Sydney, Australia) per 1 ml of alhydrogel (CSL, Parkville, Australia) in 0.9% sterile saline. SAL-treated mice received alhydrogel in 0.9% sterile saline alone. Sensitized mice (OVA-treated) were then aerochallenged with 10 mg/ml of OVA in 0.9% saline from Day 19 to Day 36, three times a day for 30 min every second day using a sidestream nebulizer, which produced particles of 13 µm (Fisher and Paykel, Sydney, Australia). Mice were tested for AHR on Day 37, bled by cardiac puncture and killed by cervical dislocation for collection of tissues. Eight mice were used per group.
Assessment of AHR to Methacholine by a Barometric Whole Body Plethysmograph AHR to the bronchoconstrictor ß-methacholine was assessed in conscious, unrestrained mice by barometric plethysmography using equipment and software from Buxco (Troy, NY). This system yields a dimensionless parameter known as enhanced pause (Penh) that reflects changes in waveform of the pressure signal from the plethysmography chamber combined with a timing comparison of early and late expiration. In OVA-treated mice, Penh is correlated with increased eosinophilia and other inflammatory indices and is used to empirically monitor airway function as described previously (22, 23). Briefly, mice were placed in a chamber and exposed to an aerosol of water (baseline readings) and then cumulative doubling concentrations of methacholine (dissolved in water to make concentrations in solution ranging from 3.1550 mg/ml). The aerosol was generated by an ultrasonic nebulizer and drawn through the chamber for 2 min at a constant flow rate. The inlet was then closed and Penh readings were taken for 3 min and averaged.
Assessment of Bronchoalveolar Lavage Fluid Inflammatory Cell Infiltration
Assessment of Histology of Lung Tissue After an overnight fixation with formalin, lung tissues representing the central and the peripheral lung tissue were horizontally sliced from the midzone of a single lobed lung and embedded in paraffin. Ribbons of 5 µm thickness were cut and stained with Charbol's chromotrophe hematoxylin (Sigma-Aldrich) for identification of eosinophils and Alcian blue/periodic acid-Schiff (Sigma-Aldrich) for enumeration of mucin-secreting cells. Eosinophils and mucus-containing cells were identified by morphologic criteria as described by Foster and colleagues (23). For frozen tissues, the entire lung was excised and sections of the trachea and lobes quickly placed into plastic embedding trays containing OCT and snapped frozen in a glass beaker containing 50 ml of isopentane (BDH-Merck, Victoria, Australia) by immersion into liquid nitrogen. Frozen tissue blocks were sectioned at 8 µm thickness and allowed to adhere onto poly-L-lysine (Sigma-Aldrich)coated glass slides at room temperature for 20 min. Sections were fixed in 100%-chilled acetone (Sigma-Aldrich) for 10 min at room temperature before tissue staining.
Detection of the Procaspase-3 and Active Caspase-3 Protein Levels by Immunohistochemistry
Detection of a Caspase Cleavage Product of Cytokeratin 18 by Immunohistochemistry
Detection of Intracellular Zn Levels Using the Zn Fluorophore Zinquin We have called the component of cellular Zn accessible to Zinquin binding "available Zn." Previous experiments have shown that Zinquin fluorescence is completely quenched by the addition of the Zn chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethyl-enediamine (TPEN). Available Zn is unlikely to include the major pool of metallothionein Zn because it has been shown in liver cytosols that Zinquin fluorescence is greatly quenched by metallothionein (24).
Co-localization of Procaspase-3 and Zn
Image Analysis
Determination of Serum and Liver Zn Levels by Atomic Absorption Spectroscopy
Statistical Analysis
The main body of results refer to four groups of mice on a protocol of dietary Zn manipulation and allergic sensitization and challenge (Figure 1B). For each parameter, two major comparisons were made:- (i) between SAL-treated and OVA-treated mice, and (ii) between diets (ZN versus ZL).
Body Weight
There was a separation of weights (P
Eosinophilia The ZN OVA-treated mice had marked, highly significant increases in eosinophils in BALF, blood, and lung tissue, compared with SAL-treated mice (Table 2), confirming the success of the allergy induction protocol. BALF cells in ZN OVA-treated animals comprised a mean ± SEM of 73.2 ± 1.9% eosinophils, 17.4 ± 2.1% lymphocytes, 8.3 ± 1.0% macrophages, and 1.2 ± 0.6% neutrophils; the number of cells recovered in the BALF fluid of ZN SAL-treated mice was too low to obtain accurate percentages (Table 2). There was no difference in the percentage of BALF eosinophils when SAL-treated or OVA-treated mice were placed on ZL diets. Thus, ZN OVA-treated mice had 73.2 ± 1.9% eosinophils compared with the ZL OVA-treated mice, which had 73.3 ± 3.1% (Table 2). Hence, dietary Zn did not influence BALF eosinophil percentages in these mice. There was no significant change in neutrophils, lymphocytes, or macrophages in the ZL OVA-treated mice.
In peripheral blood of ZN OVA-treated mice, eosinophils constituted 5 ± 0.6% of the cells, compared with 1.3 ± 0.5% in ZN SAL-treated mice (P < 0.005). There were no significant differences in percentages of lymphocytes, monocytes, or neutrophils between ZN OVA-treated and ZN SAL-treated animals (Table 2). Tissue eosinophil counts were assessed in at least six different airways of three different mice using a 100x objective lens and are expressed as mean number of eosinophils/HPF. ZN OVA-treated mice had a more than 400-fold increase in tissue eosinophils increasing from 0.1 ± 0.1 to 41.4 ± 4.4 (P < 0.005).
In contrast to BALF findings, Zn deprivation significantly increased blood eosinophil percentages in OVA-treated mice from 5.0 ± 0.6% in the ZN OVA-treated mice to 9.3 ± 0.5% in the ZL OVA-treated mice (P
Consistent with an increase in blood eosinophils, there was a significant rise in the number of infiltrating tissue eosinophils around the airways of both SAL-treated and OVA-treated mice given the ZL diet. First, in the SAL-treated groups, ZL mice had an increase in eosinophil numbers from 0.1 ± 0.1 cells/high power field (HPF) in ZN mice to 1.8 ± 0.6 cells/HPF (P
Mucus Cells
Mucus cell numbers were significantly increased in OVA-treated mice (Table 2) with ZN OVA-treated mice having a mean mucus cell count of 70.6 ± 3.2 cells/HPF, compared with 0.1 ± 0.1 cells/HPF in ZN SAL-treated mice (P
Zn deprivation increased mucus cell numbers in both SAL-treated and OVA-treated groups (Table 2). There were increases in mucus cell numbers from 0.1 ± 0.1 cells/HPF in ZN SAL-treated mice to 1.1 ± 0.3 cells/HPF in ZL SAL-treated mice (P
Serum and Liver Zn Serum Zn in ZN SAL-treated mice was 17.6 ± 5.1 µM compared with 13.2 ± 3.4 µM in the ZL SAL-treated mice, 13.5 ± 1.5 µM in the ZN OVA-treated mice, and 15.8 ± 1.7 µM in the ZL OVA-treated mice. The mean liver Zn levels were within the range of 445488 nmol/g wet weight. For all comparisons, the small changes in Zn concentrations were nonsignificant. The initial growth curves of mice on the ZL diet, however, clearly indicate that the Zn contents of the diet limited growth rates during the period of maximum growth. This functional measure is more sensitive than the measurement of total tissue or serum Zn levels in adult mice.
Intraepithelial Available Zn
Zn deprivation also significantly decreased Zinquin fluorescence, but the magnitude of the decrease was much less than that due to allergy alone. Zinquin fluorescence fell from 100.9 ± 3.2 GSU in the ZN SAL-treated mice to 92.05 ± 3.3 GSU in the ZL SAL-treated mice (P 0.05). As with effects of allergy alone, decreases occurred in both the apical and basal compartments (Figure 3A). In the OVA-treated group, Zn deprivation did not further decrease Zinquin fluorescence (47.6 ± 0.8 GSU). Figure 3B shows typical images of Zinquin fluorescence in airway epithelium of ZN SAL-treated (A), ZL SAL-treated (B), ZN OVA-treated (C) and ZL OVA-treated (D) mice. Note the substantially decreased levels of Zinquin fluorescence in the OVA-treated mice tissues when compared with the SAL-treated tissues. Figure 3A shows a typical profile line drawn across the epithelium along which fluorescence values were determined for 15 equally spaced intervals. Of interest is the apical distribution of fluorescence in the SAL-treated mice and the homogenous distribution in the OVA-treated mice (Figure 3).
Procaspase-3 Protein Levels
There was also a significant decrease in apical procaspase-3 levels in the airway epithelium of the ZL SAL-treated mice, which had a level of 190.0 ± 4.6 GSU compared with 207.8 ± 5.2 GSU in the ZN SAL-treated mice (P
Early Markers of Apoptosis
In the ZL OVA-treated mice, substantial amounts of active caspase-3 and its cleaved substrate were seen in a localized pattern, particularly along the basement membrane (D and H) and also within the subepithelial region and lamina propria (asterisk). Note also a high frequency of apoptotic bodies at the lumenal surface of the epithelium (arrowed) and in the lumen (H). Apoptotic bodies were enumerated under high magnification (x2,500) in 20 fields from duplicate slides for the different groups of mice. The mean number (± SD) of apoptotic bodies per high-powered field were 0.1 ± 0.4 for ZN SAL-treated mice and 0.3 ± 0.7 for ZL SAL-treated mice (not significant). However, there were significant increases in OVA-treated mice (P 0.005), where ZN OVA-treated mice had 2.2 ± 1.7 apoptotic bodies and the ZL OVA-treated mice had 7.0 ± 3.3 (P 0.005), suggesting that restriction of Zn further increases airway epithelial apoptosis over that due to the allergen treatment alone.
AHR
There was a significant increase (P 0.05) in AHR of mice given a ZL diet. This was best seen in the SAL-treated mice, where increases were seen at all concentrations of ß-methacholine 12.5 mg/ml (Figure 5). With the ZL OVA-treated group, although all Penh readings were higher than the corresponding readings for the ZN OVA-treated groups, significance was only seen at 50 mg/ml ß-methacholine (P 0.05, Figure 5). Figure 5 shows data from a typical experiment. These findings were confirmed in each of three separate experiments. For example, the penh readings for the ZL SAL-treated mice, at 50 mg/ml dose of ß-methacholine, were greater than those of the ZN SAL-treated mice by 52.9% (n = 4 mice), 40.4% (n = 8 mice), and 55.9% (n = 8 mice). The mean increase in AHR (50 mg/ml dose of ß-methacholine) due to Zn deficiency alone was 49.7%, compared with an increase of 106.2% due to OVA treatment alone.
In this study we have demonstrated an association between Zn deprivation and allergic airway inflammation. The major findings include (i) an increase in inflammatory indices (blood and tissue eosinophilia and mucus-secreting cell numbers) and AHR in Zn limited SAL-treated and OVA-treated mice; (ii) a reduction of Zinquin fluorescence which was associated with an increase in procaspase-3 labeling in the respiratory epithelium of OVA-treated mice; and (iii) an increase in active caspase-3 labeling in the basal region of the airway epithelium of OVA-treated mice, especially those which were Zn limited. These findings point to a hitherto unrecognized role for Zn in the respiratory system. Our previous findings that primary sheep and pig respiratory epithelial cells are rich in available intracellular Zn, and that this is co-localized with procaspase-3 in the apical cytoplasm, suggest that this Zn may have a role in the survival of these cells. In support of this, Zn depletion enhanced oxyradical-induced caspase-3 activation and apoptosis, whereas Zn supplementation had a suppressive effect (10, 11). This paper takes these findings further by focusing on whether Zn influences the key physiologic (AHR) and histologic features (tissue and blood eosinophilia and mucus-secreting cell numbers) associated with asthma. One of the main features of this study was the manipulation of Zn status via the diet to induce a mild Zn deficiency. We achieved this by giving a ZL diet containing 14 mg/kg of Zn, rather than more commonly used diets which contained less than 1 mg/kg of Zn and therefore creating a more severe level of Zn deficiency (21). Zn deficiency was demonstrated by reduction in growth rates between Days 4 and 12, which was during the first period of OVA sensitization. Growth inhibition is a sensitive marker of Zn deficiency and the growth curves clearly show that Zn was the only limiting factor to weight gain in these mice. The rationale behind inducing a mild, rather than a more severe, Zn deficiency in these mice is that this more adequately reflects the suboptimal levels found in individuals with asthma (1315, 17). This mild Zn deficiency caused significant differences in several inflammatory indices in our murine model. In two human studies conducted in the 1990s, Schwartz and Weiss reported a negative relationship between wheezing and serum Zn:Cu ratios in a population study (18), whereas Soutar and colleagues noted an increase in the prevalence of atopy, bronchial reactivity, and risks of allergic symptoms in adults with the lowest intake of dietary Zn (19). Serum Zn and Cu levels are often negatively correlated (26). Because we have previously shown that Penh values proportionally reflect changes in resistance induced by spasmogens (23), the significant differences in Penh between experimental groups likely reflect functional changes in airflow within the airways. Our finding of increased AHR in ZL mice shows a direct effect of change in dietary Zn levels on airway function, which was approximately half of that observed due to allergen treatment. This suggests that even mild Zn deficiency has a significant influence on airway function. It is possible that the lesser effects of Zn deprivation on AHR in OVA-treated mice are due to the high level of inflammation already present in these mice, as seen in Table 2. The mechanisms controlling the increased AHR in the ZL mice now need to be further investigated to determine whether this is an effect primarily on the smooth muscle or rather an effect on the airway epithelium. One possible mechanism of action is via inhibitory effects of Zn on muscarinic and nicotinic receptors (27, 28). One scenario is that Zn deprivation facilitates activation of muscarinic receptors, calcium channels, and calcium influx in smooth muscle cells, resulting in enhanced bronchoconstriction. Similar effects on airway epithelial cells may influence other factors. Alternatively, increased AHR in ZL mice may be due to the increase in the numbers of mucus-secreting cells noted in our ZL mice. Future studies will determine whether creating a more severe Zn deficiency in these mice further exacerbates AHR and whether incubation of airway smooth muscle cells with an exogenous Zn salt blocks ß-methacholineinduced activation of muscarinic receptors in vitro. Other effects of Zn deficiency on AHR include enhanced inflammation due to shifts in the balance of lymphocyte subsets toward the proinflammatory Th2 subset (29, 30), increases in activation of mast cells and eosinophils (31, 32), and increases in proinflammatory cytokines (33). The lack of effect of Zn deprivation on numbers of BALF eosinophils may relate to the severity of Zn deprivation created or to the kinetics of the response. This now needs to be investigated in mice receiving a broader range of Zn diets (inducing different levels of Zn deficiency) and at different time points after induction of airway inflammation.
This study has provided the first information on lung epithelial Zn levels in allergic airway inflammation. One of the major findings of this study was the substantial loss of airway epithelial Zn in the lungs of the OVA-treated mice. The Zinquin fluorescence in the airway epithelium of the different groups of mice did not correlate with systemic levels of Zn in serum and liver as determined by AAS. This suggests that the mechanism of Zn loss is restricted to the airways. This may be due to one or more of the following mechanisms. The reduction in available Zn was homogenous and occurred in both the apical and basal compartments of the epithelium, which suggests that there is an overall loss of Zn from the epithelium rather than from one cell type. However, it must be formally determined whether this loss is predominantly in the ciliated cells, in the mucus cells, or in both, because in the OVA-treated mice
One of the implications of Zn loss in the OVA-treated airway epithelium is the potential for enhanced apoptosis, because Zn is a potent suppressor of this mechanism of cell death. Zn is thought to act by blocking the activation of caspase-3 (34, 35). In light of this, the increase in procaspase-3 levels in the OVA-treated tissues is very interesting. The increased levels of procaspase-3 will render these cells more susceptible to apoptosis, which may be an important factor in the fragility of the epithelium in asthma. Apoptosis of bronchial epithelial cells in humans with asthma has recently been suggested by Benayoun and colleagues, who showed increased peroxisome proliferatoractivated receptor The mechanism behind the marked decrease in available Zn in the airway epithelium of OVA-treated mice is not known. This decrease in Zinquin fluorescence may represent a net reduction in epithelial Zn concentration and/or an incorporation of a greater proportion of Zn into metallothionein, which attenuates Zinquin fluorescence (24). If Zn has indeed been lost from the airway epithelium, several factors may play a part. First, losses of cellular Zn are associated with enhanced cell turnover (26) a feature which is also found in individuals with asthma, in whom there is shedding of Zn-rich airway epithelial cells and eosinophils into the airway lumen. Second, Zn may be lost from the airway epithelial cells by secretion into the epithelial lining fluid or by binding to the negatively charged muco-polysaccharides in the mucin layer. Third, redistribution of Zn from certain tissues via the plasma to the liver is a common feature of inflammation (8), although this is unlikely, given our finding of a trend toward decreased liver Zn in our OVA-treated ZN mice, compared with SAL-treated mice. If the reduction of available Zn was due to a transfer of Zn to metallothionein within the airway epithelial cells, the resultant effect on caspase-3 activation would be similar to an absolute loss of this metal. Maret and colleagues have demonstrated that thionein, the apo-form of metallothionein, can remove Zn from inhibitory sites and reactivate several enzymes, including caspase-3 (38). This study provides new data on the inter-relationship between Zn and airway epithelial cells, which may lead to a greater understanding of the association between Zn deficiency and airway disease. This provides an impetus for research to understand the molecular, biochemical, and cellular mechanisms for the possible beneficial roles of Zn in asthma.
The authors are grateful to Dr. Dianne Webb for helpful discussions. Many thanks to Luke Carey for assistance with diets and Zn measurements, Dr. Meredith Wallwork for assistance with the UV laser confocal microscope, Josh McGee for his creative biotechnical engineering skills, Ken Porter, Bronwyn Hutchens, Adrian Hines for help with the animals, and to Barbara Chapman and Maya Kezeli for assistance with immunohistochemistry. The authors would also like to acknowledge the Queen Elizabeth Hospital Research Foundation and the Adelaide University for their financial support. A.Q.T. is a recipient of the Benjamin Poulton University of Adelaide Postgraduate Scholarship and the CRC for Asthma Supplementary Scholarship. Received in original form December 26, 2001 Received in final form April 30, 2002
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||